Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: A Turkish Oncology Group study
Erişim
info:eu-repo/semantics/closedAccessTarih
2022Yazar
Hızal, MutluBilgin, Burak
Paksoy, Nail
Kılıçkap, Sadettin
Atcı, Muhammed Mustafa
Kahraman, Seda
Keskinkılıç, Merve
Bilgetekin, İrem
Ayhan, Murat
Tural, Deniz
Eren, Önder
Akkoç Mustafayev, Fatma Nihan
Yaman, Şebnem
Tatlı, Ali Murat
Bayram, Ertuğrul
Kutlu, Yasin
Ertürk, İsmail
Özcan, Erkan
Gülmez, Ahmet
Korkmaz, Mustafa
Akagündüz, Baran
Erdem, Dilek
Akın Telli, Tuğba
Aksoy, Asude
Üskent, Necdet
İriağaç, Yakup
Köse Baytemür, Naziyet
Aydın, Dinçer
Sakalar, Teoman
Arak, Haci
Selçukbiricik, Fatih
Ergün, Yakup
Korkmaz, Taner
Ak, Naziye
Ünal, Çağlar
Akdeniz, Nadiye
Özgün, Mehmet Alpaslan
Öksüzoğlu, Berna
Yalçın, Bülent
Öztop, İlhan
Algın, Efnan
Sakin, Abdullah
Aydıner, Adnan
Yumuk, Perran Fulden
Şendur, Mehmet Ali Nahit
Üst veri
Tüm öğe kaydını gösterKünye
Hızal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S. ... Şendur, M. A. N. (2022). Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: A Turkish Oncology Group study. Future Oncology, 18(23), 2573-2582. https://doi.org/10.2217/fon-2022-0083Özet
Aims: In this multicenter study, the authors aimed to determine the real-life efficacy and safety of first-line alectinib. Materials & methods: This retrospective trial included advanced-stage, ALK-positive non-small-cell lung cancer patients who were treated with first-line alectinib in terms of ALK-tyrosine kinase inhibitors, regardless of previous chemotherapy. The co-primary end points were progression-free survival both for all patients and for the treatment-naive population. The secondary end points were overall response rate, overall survival, rate of CNS progression and safety. Results & conclusion: A total of 274 patients (n = 177 for treatment-naive patients) were enrolled in the study. The median progression-free survival was 26 and 28.8 months for all patients and the treatment-naive group, respectively. The overall response rate, CNS progression rate and 1-year overall survival ratio were 77.9, 12.4 and 77%. Alectinib is a highly effective therapy with a favorable safety profile.
WoS Q Kategorisi
Q3Scopus Q Kategorisi
Q2Kaynak
Future OncologyCilt
18Sayı
23Koleksiyonlar
- Makale Koleksiyonu [3801]
- PubMed İndeksli Yayınlar Koleksiyonu [4264]
- Scopus İndeksli Yayınlar Koleksiyonu [6620]
- WoS İndeksli Yayınlar Koleksiyonu [6696]